Facility along Cambridge Street will provide exceptional care, increased capacity and strengthen ties to West End and Beacon Hill neighborhoods.
Patients seen in the Corrigan Minehan Heart Center at Massachusetts General Hospital can join the Cardiovascular Biorepository (CVBio), a project to study genetic and other factors that may lead to heart and blood vessel diseases. Read the answers to frequently asked questions to learn more
What is the CVBio?
The Cardiovascular Biorepository (CVBio) at Massachusetts General Hospital helps researchers at the Corrigan Minehan Heart Center conduct research. The CVBio supports studies on genetic and other factors that can lead to heart and blood vessel diseases. If you join our biobank, our researchers will use samples of your blood and your medical history for research. By taking part in this project, you are helping efforts to predict, prevent and treat cardiovascular diseases for generations to come.Learn more about the CVBio
How do I join?
You can learn more about the CVBio and how to join in one of two ways:
- Enroll before or after your appointment with a Corrigan Minehan Heart Center provider, who may suggest participation in the biorepository with you, or
- Contacting the CVBio staff at 617-643-1699
If you decide to join the project, we will ask you to fill out a consent form. You will also need to provide some health information for our database. Our staff will take from you a small blood sample (3 ½ tablespoons). This blood sample and your health information will be stored by Mass General for future studies.
Joining this project is optional. Your choice to join will not affect the care you get at Mass General or other hospitals.
How is my privacy protected?
We take patient privacy very seriously. After you join the CVBio, we will:
- Use your information for research only
- Keep your information private so that only researchers and certain staff can see it
- Keep your identity separate from research records. We will give each person’s sample a unique study number and the numbers will not be matched to identities
As part of the CVBio, we may:
- Use your Mass General Brigham medical records for research only
- Ask you in the future to provide more information or more blood samples or to participate in additional studies (you can always say no)
Why should I join the CVBio?
By joining the CVBio, you will help research that may improve health care for future generations. Your decision of whether or not to join the CVBio will not affect the care you receive at Mass General or other hospitals.
Will I get results of testing done on my blood samples?
We do not expect to send any personal results to patients who join. However, we may send a letter updating participants on general results from research supported by the CVBio.
What are the risks of joining the CVBio?
The main risk from joining this project is losing some of your privacy. We will protect your samples and information as best as we can. However, we cannot guarantee that your information will not be seen by others not part of our research team. We do not expect this to happen, though, as it is very unlikely.
If you choose to join, please read the consent form [pdf icon] fully and ask any questions that you may have beforehand. This form will fully explain all of the risks and gains of taking part in the project. It will also give more information about the types of research that your sample could be used for.
To learn more about the CVBio, call 617-643-1699 or email CVBio@partners.org
Related News and Articles
- Press Release
- Sep | 23 | 2022
The wrist-worn devices may identify patients who would benefit from stroke prevention therapies.
- Patient Education
- May | 24 | 2022
On May 24, 2022, the Massachusetts General Hospital Transplant Center held a virtual, fireside chat to share the latest updates on COVID-19 and transplantation.
- Press Release
- Apr | 18 | 2022
Women who had experienced infertility had a 16% increased risk of heart failure compared with women who did not have an infertility history.
- Press Release
- Mar | 3 | 2022
Handheld devices for A-fib screening may be most effective in the oldest adults during primary care visits
Advanced consumer technology has produced small electrocardiogram devices that could be efficiently deployed in point-of-care screening for atrial fibrillation, though the proportion of cases detected among all patients 65 and older is small.
- Press Release
- Mar | 2 | 2022
Mutations in genes that direct the production of fibrillar collagens, essential components of blood vessel walls, appear to predispose individuals to SCAD.